Clinical TrialHealthy VolunteersMDMAPlaceboCompleted

Come closer: a neurobiological analysis of the prosocial effects of MDMA

Double-blind, placebo-controlled crossover study (n=24) testing single-dose MDMA (75 mg), intranasal oxytocin (48 IU), MDMA+5-HT1A blocker (pindolol 20 mg), and placebo in healthy MDMA-experienced volunteers to investigate prosocial effects and mechanisms.

Ask Blossom about this trial
Target Enrollment
24 participants
Study Type
Phase NA interventional
Design
Randomized, double Blind

Continue exploring

Continue exploring this trial

Move from the registry record to the most relevant public research context.

Compound research: MDMATopic research: Healthy VolunteersResearch in Netherlands

Detailed Description

Randomized, double-blind, placebo-controlled within-subject crossover (Latin square) with four test days separated by a minimum 7-day washout; treatments: MDMA 75 mg oral capsule, MDMA+5-HT1A blocker (pindolol 20 mg), intranasal oxytocin (48 IU total), and placebo.

Outcomes include objective computer tasks of empathy and social interaction, control word-learning task, and blood measurements of MDMA, oxytocin and other treatment concentrations; also assessment of the moderating effect of serotonin transporter genotype.

Study Protocol

Preparation

sessions

Dosing

4 sessions

Integration

sessions

Study Arms & Interventions

MDMA

experimental

Single-dose MDMA 75 mg (oral) as one condition of a 4-condition crossover (Latin square).

Interventions

  • MDMA75 mg
    via Oral• single dose• 1 doses total

    MDMA 75 mg capsule.

MDMA + pindolol

experimental

MDMA 75 mg with pindolol 20 mg (5-HT1A blocker) as combination condition; crossover.

Interventions

  • MDMA75 mg
    via Oral• single dose• 1 doses total
  • Compound20 mg
    via Oral• single dose

    Pindolol (Visken®) 20 mg capsule, peak ~60 min; given in combination condition.

Oxytocin

experimental

Intranasal oxytocin condition (48 IU total) as one arm of the crossover.

Interventions

  • Compound48 IU
    via Other• single dose• 1 doses total

    Syntocinon® intranasal spray, total 48 IU (multiple inhalations as per protocol).

Placebo

inactive

Matching placebo condition; part of 4-condition crossover.

Interventions

  • Placebo
    via Oral• single dose• 1 doses total

    Matching placebo capsules/sprays for each active condition.

Participants

Ages
18 – 40
Sexes
Male & Female

Inclusion Criteria

  • Healthy volunteers aged 18–40 years who have used ecstasy/MDMA between 3 and 200 times lifetime and at least once in the last year.
  • Informed consent and ability to comply with study procedures.

Exclusion Criteria

  • Never used ecstasy/MDMA.

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

  • Status
    Completed
  • Phase
    Phase NA
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment24 participants
  • Timeline
    Start: 2011-06-14
    End: 2012-01-01
  • Compounds
    MDMAPlacebo
  • Topic
    Healthy Volunteers

Locations

Netherlands

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans